FPR3 and obstructive sleep apnea syndrome: Intracellular FPR3 expression of M1 monocyte was significantly decreased in treatment-naive OSA (3.29±1.54, MFI, p<0.001/adjusted p<0.001) and severe OSA on CPAP (3.17±1.71 MFI, P<0.001/adjusted p = 0.002) groups as compared with that in HS (7.54±2.75 MFI) group (Fig 2D), while FPR3 expression of M2a monocyte was significantly decreased in the treatment-naïve OSA group as compared with that in the HS group (6.21±5.14 versus 11.38±5.12; p = 0.016/adjusted p = 0.001; Fig 2E).